Ernexa Therapeutics Inc.
ERNA
$1.47
-$0.0201-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 201.23% | 365.22% | 755.88% | 1,072.55% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 201.23% | 365.22% | 755.88% | 1,072.55% | -- |
| Cost of Revenue | -117.54% | -85.83% | -59.32% | -4.71% | 584.00% |
| Gross Profit | 404.44% | 478.79% | 389.29% | 466.39% | -260.00% |
| SG&A Expenses | -52.99% | -32.69% | -9.81% | 17.10% | 28.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.69% | -30.73% | -14.03% | 2.18% | -4.60% |
| Operating Income | 46.50% | 32.88% | 16.57% | 0.49% | 5.30% |
| Income Before Tax | -82.53% | -101.11% | -105.39% | -125.01% | -10.38% |
| Income Tax Expenses | 780.00% | 950.00% | 1,100.00% | -63.41% | -109.26% |
| Earnings from Continuing Operations | -82.71% | -101.29% | -105.55% | -124.62% | -10.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.71% | -101.29% | -105.55% | -124.62% | -10.08% |
| EBIT | 46.50% | 32.88% | 16.57% | 0.49% | 5.30% |
| EBITDA | 46.61% | 33.12% | 16.90% | 0.81% | 5.43% |
| EPS Basic | -18.98% | -46.86% | -79.41% | -98.73% | 21.50% |
| Normalized Basic EPS | 67.76% | 42.12% | 12.63% | -5.29% | 21.91% |
| EPS Diluted | -18.98% | -46.86% | -79.41% | -98.73% | 21.50% |
| Normalized Diluted EPS | 67.76% | 42.12% | 12.63% | -5.29% | 21.91% |
| Average Basic Shares Outstanding | 707.48% | 376.13% | 156.87% | 11.19% | 27.33% |
| Average Diluted Shares Outstanding | 707.48% | 376.13% | 156.87% | 11.19% | 27.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | 0.75% | 0.76% | 0.56% | 0.09% |